Medicamen Biotech Limited (MEDICAMEQ) AI Stock Analysis

• Market Cap: ₹3.26B
• Dividend Yield: 0.26%
• Average Volume (3M): 2.40K
• Price to Earnings (P/E): 56.5
• Beta (1Y): 1.52
• Revenue Growth: -9.16%
• EPS Growth: 49.09%
• Country: IN
• Employees: 378
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.61
• Shares Outstanding: 13,562,815
• 10 Day Avg. Volume: 3,620
• 30 Day Avg. Volume: 2,395
• PEG Ratio: -2.50
• Price to Book (P/B): 2.95
• Price to Sales (P/S): 3.86
• P/FCF Ratio: -52.55
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: ₹233.00 ▼(-36.49% Downside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is anchored by mixed financial performance: a solid balance sheet and decent operating margins are offset by weak cash generation (negative operating and free cash flow). Technicals further weigh on the rating due to a clear downtrend (below major moving averages and negative MACD). Valuation is also a headwind given the high P/E and minimal dividend yield.

Positive Factors

Solid balance sheet

Moderate leverage and a strong equity ratio support long-term solvency and financial flexibility. This structure helps the company absorb industry shocks, preserve access to credit, and fund strategic investments without excessive refinancing risk over the next several quarters.

Negative Factors

Negative operating and free cash flow

Persistent negative operating and free cash flow undermines the company's ability to self-fund capex, working capital, and debt service. If it continues, management may need external financing, which can dilute returns or constrain strategic investments and long-term stability.

Medicamen Biotech Limited Business Overview & Revenue Model

Company Description

Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, and ointments. It also provides oral rehydration solution,...

Read more

Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, and ointments. It also provides oral rehydration solution,...

How the Company Makes Money

Medicamen Biotech Limited makes money primarily by selling pharmaceutical formulations (finished dosage medicines) to customers in India and overseas. Revenue is generated from (1) domestic formulation sales through its marketing and distribution ...

Read more

Medicamen Biotech Limited makes money primarily by selling pharmaceutical formulations (finished dosage medicines) to customers in India and overseas. Revenue is generated from (1) domestic formulation sales through its marketing and distribution ...

Medicamen Biotech Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	1.65B	1.63B	1.79B	1.41B	1.15B	1.13B
Gross Profit	634.54M	389.90M	852.01M	687.74M	479.88M	335.16M
EBITDA	210.79M	201.02M	245.66M	277.12M	258.07M	204.25M
Net Income	101.58M	71.08M	109.31M	148.44M	148.98M	121.29M
Balance Sheet
Total Assets	3.67B	2.97B	2.95B	2.79B	2.26B	1.94B
Cash, Cash Equivalents and Short-Term Investments	436.79M	37.59M	147.86M	207.79M	38.25M	38.91M
Total Debt	386.49M	332.53M	311.12M	257.09M	257.96M	188.19M
Total Liabilities	916.99M	841.04M	875.67M	851.03M	792.24M	611.18M
Stockholders Equity	2.75B	2.13B	2.07B	1.93B	1.46B	1.33B
Cash Flow
Free Cash Flow	-145.81M	-119.32M	-130.31M	-128.94M	-44.99M	-51.94M
Operating Cash Flow	-124.06M	-98.59M	-67.44M	-62.93M	41.09M	127.72M
Investing Cash Flow	-15.21M	-23.78M	-55.63M	-58.80M	-84.73M	-178.13M
Financing Cash Flow	538.49M	12.16M	63.13M	291.27M	42.98M	58.39M

Medicamen Biotech Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 366.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDICAMEQ, the sentiment is Negative. The current price of 366.9 is above the 20-day moving average (MA) of 252.06, above the 50-day MA of 299.11, and above the 200-day MA of 352.90, indicating a bearish trend. The MACD of -19.84 indicates Negative momentum. The RSI at 36.53 is Neutral, neither overbought nor oversold. The STOCH value of 41.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MEDICAMEQ.

Medicamen Biotech Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	79 Outperform	₹12.96B	10.01	―	―	13.32%	218.38%
SAKAR	66 Neutral	₹11.86B	22.21	―	―	24.20%	55.01%
INDSWFTLAB	65 Neutral	₹12.31B	18.86	―	―	-37.70%	-19.79%
ZIMLAB	63 Neutral	₹3.47B	19.99	―	―	-5.82%	-59.22%
MEDICAMEQ	55 Neutral	₹3.26B	56.53	―	0.26%	-9.16%	49.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NECLIFE	48 Neutral	₹2.43B	7.63	―	―	-30.27%	-3470.06%

Medicamen Biotech Limited Corporate Events